Novo has another long-acting insulin, Tresiba, on the market. "Novo Nordisk will phase out, then permanently discontinue Levemir in the U.S. on December 31, 2024," the company said in a statement.

Levemir’s U.S. sales amounted to 1.27 billion Danish crowns ($185.6 million) in 2023, while Tresiba, Novo Nordisk’s other daily long-acting insulin, generated 1.33 billion crowns.

The drug’s maker, Novo Nordisk, announced in November that it was discontinuing Levemir Flexpen and Levemir subcutaneous injection solutions. Supply is expected to deplete by April, when tens of ...

Novo Nordisk previously told USA TODAY it would discontinue U.S. sales of Levemir due to global manufacturing constraints and the availability of other forms of insulin.

Earlier this year, Novo opted to slash Levemir’s price point by 65%, a move which was to go in effect come Jan. 1. The company also sliced the cost of its NovoLog insulin by 75% and matched ...

Novo Nordisk discontinuing Levemir has been stressful, taking a significant amount of time and my prescriber’s time and my pharmacist’s time, and is super expensive.

The Novo spokesperson said in a statement to Reuters on Friday that Levemir was not discontinued due to "success" of the company's newer medicines Wegovy and Ozempic, widely prescribed for weight ...

Patients with type 2 diabetes are less likely to reach target blood sugar levels on Novo Nordisk's long-lasting insulin Levemir than on shorter-acting products, researchers said on Friday.

Drug maker Novo Nordisk announced Tuesday the additional approval of Levemir (insulin detemir [rDNA origin]). The insulin already was approved for Type 1 diabetes in older children and adults and ...

Novo has another long-acting insulin, Tresiba, on the market. "Novo Nordisk will phase out, then permanently discontinue Levemir in the U.S. on December 31, 2024," the company said in a statement.